Can I Take Melatonin with Lantus (Insulin Glargine)?

What Is the Interaction Between Melatonin and Lantus?

The interaction is pharmacodynamic, not pharmacokinetic. Melatonin does not change how Lantus is absorbed, distributed, or cleared. Instead, melatonin acts on MT1 and MT2 receptors expressed on pancreatic beta cells and reduces cyclic AMP (cAMP) and cyclic GMP (cGMP) signaling, which blunts glucose-stimulated insulin secretion. The result is a modest shift toward higher blood glucose, particularly overnight when basal insulin is doing its primary work.

This distinction matters clinically. No dose adjustment to Lantus itself is required just because melatonin is present. The concern is whether your glucose targets remain met, not whether Lantus is behaving differently in your bloodstream.

Pharmacokinetic Profile: Why They Do Not Directly Interfere

Insulin glargine is a long-acting analog with a relatively flat 24-hour absorption profile and an elimination half-life of roughly 12 hours at the subcutaneous depot. Melatonin taken orally has a half-life of 20 to 50 minutes, peaks within 1 hour, and is metabolized primarily by CYP1A2 in the liver to 6-sulphatoxymelatonin. These two compounds do not share a metabolic pathway, do not compete for plasma protein binding sites, and do not alter each other's pharmacokinetics in any documented way. CYP1A2 interaction data reviewed in the NIH LiverTox database.

Pharmacodynamic Profile: Where the Concern Lives

The real story is at the receptor level. MT1 and MT2 receptor expression in human islets was confirmed in a key 2009 study by Ramracheya et al., published in Diabetologia, which showed that melatonin application to isolated human islets significantly inhibited both insulin and glucagon secretion in a dose-dependent manner. Exogenous melatonin at physiologic-to-supraphysiologic concentrations therefore reduces the endogenous insulin contribution that ordinarily helps basal insulin coverage.

For a person using Lantus who still has some residual beta-cell function (most type 2 patients, and some type 1 patients in partial remission), this blunting effect can widen the gap that Lantus alone must cover overnight.

What Does the Clinical Evidence Actually Show?

Several well-designed human studies have examined melatonin's effect on glucose metabolism, and the findings are consistent but context-dependent.

The MTNR1B Genetic Link

A genome-wide association study published in Nature Genetics (Lyssenko et al., 2009, N=6,736 initially, replicated in 12,000+) identified common variants in MTNR1B, the gene encoding the MT2 receptor, as strongly associated with elevated fasting plasma glucose and increased risk of type 2 diabetes. Carriers of the rs10830963 risk allele of MTNR1B showed a 20 to 30% greater rise in fasting glucose in response to oral melatonin in subsequent mechanistic studies.

This means genetic background modifies your personal risk. Approximately 30% of individuals of European ancestry carry at least one copy of this risk allele, and those individuals may experience a more pronounced glucose rise when adding melatonin.

Controlled Human Challenge Studies

A randomized crossover trial by McMullan et al. (2013) in adults without diabetes gave 0.5 mg melatonin or placebo 30 minutes before a standard oral glucose tolerance test. The melatonin group showed significantly higher glucose at 30 and 60 minutes post-load (P<0.05), with no change in fasting insulin, suggesting the effect operated through secretion impairment rather than insulin resistance. The absolute glucose difference was modest, roughly 8 to 10 mg/dL at peak, but the direction of effect was consistent across participants.

A separate study by Rubio-Sastre et al. (2014) in 21 healthy women tested 5 mg melatonin at both morning and evening timing. Evening melatonin produced a significantly greater impairment of glucose tolerance than morning melatonin, consistent with the hypothesis that nighttime melatonin use compounds the natural circadian dip in insulin sensitivity. For Lantus users taking their dose at bedtime, this timing overlap is directly relevant.

What the ADA Says About Sleep and Glucose

The American Diabetes Association 2024 Standards of Care, Section 5 (Facilitating Positive Health Behaviors), state that "poor sleep quality and insufficient sleep duration are associated with hyperglycemia, higher HbA1c, and increased risk of diabetes complications." The ADA does not list melatonin as contraindicated in diabetes, but it flags that any intervention affecting sleep architecture or circadian rhythm deserves glucose-monitoring follow-up. The full ADA Standards of Care are available at diabetesjournals.org.

Does Melatonin Dose Matter?

Yes, dose matters considerably. The human pancreatic beta-cell studies used concentrations ranging from 1 nanomolar (physiologic nighttime peak) to 1 micromolar (supraphysiologic, equivalent to roughly 5 to 10 mg oral dose), and inhibitory effects on insulin secretion scaled with concentration.

Low-Dose Melatonin (0.5 to 1 mg)

At 0.5 mg, plasma melatonin peaks at approximately 500 to 800 pg/mL, which is within 2 to 3 times the natural nighttime peak. The glucose impact in challenge studies at this dose is statistically detectable but clinically small in most people. For a Lantus user whose overnight glucose typically runs between 90 and 120 mg/dL, a 5 to 10 mg/dL upward shift may still keep them within a safe range.

High-Dose Melatonin (5 to 10 mg)

At 5 to 10 mg, which is the dose range found in most U.S. Over-the-counter products, plasma melatonin can reach 3,000 to 10,000 pg/mL. This is 10 to 30 times the natural peak. The Rubio-Sastre 2014 study used 5 mg and found a glucose area-under-the-curve increase of roughly 18% following an evening oral glucose load. For a Lantus user whose basal dose is titrated tightly to a fasting target, this represents a clinically meaningful shift that warrants either a dose reassessment or a switch to a lower melatonin dose.

Extended-Release Formulations

Extended-release melatonin (such as Circadin 2 mg, approved in the EU) maintains lower but prolonged plasma levels through the night. One 2011 randomized controlled trial in type 2 diabetes patients (N=36) found Circadin 2 mg over 3 weeks did not significantly change HbA1c or fasting glucose, suggesting prolonged low-level exposure may be less new than a single large bolus. This formulation is not widely available in the U.S. As a prescription product, but the finding does support the principle that lower sustained doses carry less risk than high bolus doses.

How Does This Interaction Affect Lantus Specifically Compared to Other Insulins?

Lantus (insulin glargine U-100, or Toujeo at U-300) provides basal coverage with minimal peak, making it the insulin most dependent on endogenous insulin secretion to handle any incremental overnight glucose load. Rapid-acting insulins like lispro or aspart are dosed to cover meals and can be adjusted meal-to-meal. Lantus cannot be corrected the same way in real time.

The Overnight Window Is the Critical Period

Lantus users typically inject once daily, either at bedtime or in the morning. When injected at bedtime, peak subcutaneous depot activity aligns with the first 4 to 8 hours of sleep, exactly when melatonin's secretion-inhibiting effects are strongest. The 3 AM glucose nadir that many type 1 patients monitor specifically reflects this overlap.

A practical risk-stratification framework for Lantus users considering melatonin:

Tier 1 (Lower risk): Type 2 diabetes, HbA1c <7.5%, morning Lantus injection, using 0.5 mg melatonin. Recommend self-monitoring fasting glucose for 14 days. No prescriber contact required before starting, but inform at next visit.

Tier 2 (Moderate risk): Type 2 diabetes, HbA1c 7.5 to 9%, bedtime Lantus injection, or any dose above 1 mg melatonin. Recommend informing prescriber before starting, check fasting glucose daily for 2 weeks, and report if fasting glucose rises more than 20 mg/dL above usual.

Tier 3 (Higher risk): Type 1 diabetes on any Lantus dose, type 2 with HbA1c >9%, history of nocturnal hypoglycemia, or use of CGM showing frequent overnight lows. Discuss with prescriber before any melatonin use. Consider a CGM-guided 3 to 5 day trial if the prescriber agrees.

Does the Brand (Lantus vs. Basaglar vs. Toujeo) Change the Risk?

No. Basaglar is a biosimilar to Lantus with the same active molecule, glargine. Toujeo is glargine U-300 with a more concentrated depot that flattens the profile further. The melatonin interaction operates at the beta-cell receptor level, not at the insulin molecule level, so brand does not change the pharmacodynamic risk calculus.

Monitoring: What to Actually Measure

Knowing that the interaction exists is only useful if you have a plan to detect it.

Self-Monitoring of Blood Glucose (SMBG)

For Lantus users without a continuous glucose monitor, check fasting blood glucose (before eating, after waking) every morning for the first 14 days after adding melatonin. Record results. If fasting glucose is consistently above 130 mg/dL when it was previously below 110 mg/dL, contact your prescriber.

Continuous Glucose Monitoring (CGM)

CGM data from devices like the Dexterity G7 or FreeStyle Libre 3 allows you to see overnight glucose trends directly. Look at the time-in-range percentage for 70 to 180 mg/dL during the 10 PM to 7 AM window specifically. The ADA recommends a time-in-range target of >70% for most adults with diabetes, as outlined in the 2024 Standards of Care.

A drop of more than 5 percentage points in overnight time-in-range after starting melatonin is a signal to reassess.

HbA1c

HbA1c reflects 3-month average glucose and will detect a sustained melatonin-driven glucose elevation at the next routine check. HbA1c alone is insufficient for short-term monitoring of this interaction because it averages out acute shifts, but it remains a useful long-term safety check.

Are There Safer Alternatives for Sleep in Lantus Users?

Not all sleep aids carry the same glucose risk. This comparison is not exhaustive, but the options most frequently asked about are worth addressing directly.

Magnesium Glycinate

Some evidence suggests that magnesium supplementation may improve sleep latency and actually improve insulin sensitivity rather than worsen it. A meta-analysis published in Nutrients (2021) found magnesium supplementation modestly reduced fasting glucose (mean reduction 0.41 mmol/L) in people with type 2 diabetes, though the effect size varied by baseline magnesium status. Magnesium and insulin sensitivity meta-analysis at PubMed. Magnesium glycinate at 200 to 400 mg is generally considered a lower-glucose-risk sleep support option for Lantus users.

L-Theanine

L-theanine (100 to 200 mg) promotes alpha-wave relaxation without sedation and has no documented interaction with insulin signaling pathways. No human trials have examined a direct L-theanine plus insulin glargine interaction, so the absence of evidence is not the same as confirmed safety, but the mechanism is substantially different from melatonin's MT receptor pathway.

Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is the first-line treatment for chronic insomnia per the American Academy of Sleep Medicine and carries zero pharmacologic interaction risk. For Lantus users with persistent sleep difficulty, a referral to a CBT-I program is the option with the cleanest glucose safety profile.

Practical Steps If You Are Already Taking Both

Some people reading this are already taking melatonin alongside Lantus. Here is a specific action plan.

First, do not stop melatonin abruptly if you have been taking it for more than a few weeks. Abrupt discontinuation can transiently disrupt sleep, which itself raises cortisol and worsens glucose control.

Second, measure fasting glucose for three consecutive mornings before making any changes. This gives you a baseline to compare against after any adjustment.

Third, consider stepping the melatonin dose down. If you are taking 5 mg or 10 mg, try 1 mg for 2 weeks and recheck fasting glucose. The FDA has not approved any specific melatonin dose because it is sold as a dietary supplement in the U.S., so dose selection is largely empirical. The pharmacokinetic evidence strongly suggests 0.5 to 1 mg is adequate for sleep onset in most adults and carries substantially less beta-cell inhibition than 5 to 10 mg doses.

Fourth, bring your glucose log to your next Lantus prescriber visit. Even if your numbers look unchanged, your care team needs to know what supplements you are taking. A 2020 survey published in Diabetes Care found that fewer than 40% of adults with diabetes disclosed supplement use to their endocrinologist without being specifically asked. Supplement disclosure in diabetes care, Diabetes Care journal.

Special Populations and Considerations

Type 1 Diabetes

Type 1 patients have minimal or zero endogenous insulin secretion, which means melatonin's inhibition of beta-cell secretion has little incremental effect on the insulin-deficiency side of the equation. The bigger concern for type 1 patients is whether melatonin-driven changes in sleep architecture alter growth hormone secretion, cortisol timing, or dawn phenomenon intensity, all of which affect early-morning glucose and the adequacy of the Lantus dose. Careful overnight CGM monitoring is particularly important in this group.

Pregnancy

Melatonin safety in pregnancy has not been established in controlled trials. Insulin requirements change substantially across trimesters. The ACOG does not recommend melatonin supplementation during pregnancy due to insufficient safety data. Pregnant individuals using Lantus should avoid melatonin unless specifically approved by their obstetric team.

Older Adults

CYP1A2 activity declines with age, meaning melatonin clearance slows. An 80-year-old taking 3 mg melatonin may sustain plasma levels equivalent to a 40-year-old taking 6 mg. This population also tends to have longer Lantus duration of action due to reduced subcutaneous blood flow. Starting with 0.5 mg and monitoring carefully is especially important for patients over 65.